Aptahem AB (publ) (APTA.ST)
SEK 1.62
(0.94%)
SEK 1.62
(0.94%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 63.02 Million SEK | -9.4% |
| 2022 | 69.56 Million SEK | 26.29% |
| 2021 | 55.08 Million SEK | 81.36% |
| 2020 | 30.37 Million SEK | 18.31% |
| 2019 | 25.67 Million SEK | -27.04% |
| 2018 | 35.18 Million SEK | 14.43% |
| 2017 | 30.75 Million SEK | 40.06% |
| 2016 | 21.95 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 65.62 Million SEK | 1.92% |
| 2024 Q1 | 64.39 Million SEK | 2.17% |
| 2023 Q2 | 63.79 Million SEK | -1.46% |
| 2023 Q4 | 63.02 Million SEK | 3.64% |
| 2023 Q3 | 60.81 Million SEK | -4.67% |
| 2023 FY | 63.02 Million SEK | -9.4% |
| 2023 Q1 | 64.73 Million SEK | -6.94% |
| 2022 Q2 | 60.56 Million SEK | -15.0% |
| 2022 Q4 | 69.56 Million SEK | 16.91% |
| 2022 Q3 | 59.5 Million SEK | -1.75% |
| 2022 Q1 | 71.25 Million SEK | 29.35% |
| 2021 Q2 | 26.89 Million SEK | 0.0% |
| 2021 Q4 | 55.08 Million SEK | -11.72% |
| 2021 Q3 | 62.39 Million SEK | 132.02% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| 2cureX AB (publ) | 16.62 Million SEK | -279.097% |
| Abliva AB (publ) | 87.49 Million SEK | 27.971% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 27.617% |
| AcouSort AB (publ) | 34.51 Million SEK | -82.612% |
| Active Biotech AB (publ) | 44 Million SEK | -43.239% |
| Alzinova AB (publ) | 123.18 Million SEK | 48.839% |
| Amniotics AB (publ) | 26.08 Million SEK | -141.604% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -135.493% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -937.106% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 46.792% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 95.499% |
| BioArctic AB (publ) | 1.18 Billion SEK | 94.686% |
| Biosergen AB | 7.2 Million SEK | -775.225% |
| Biovica International AB (publ) | 131.4 Million SEK | 52.039% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -1.405% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 96.684% |
| Camurus AB (publ) | 1.9 Billion SEK | 96.696% |
| Cantargia AB (publ) | 223.71 Million SEK | 71.828% |
| Corline Biomedical AB | 100.1 Million SEK | 37.041% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -323.868% |
| CombiGene AB (publ) | 120.61 Million SEK | 47.746% |
| Cyxone AB (publ) | 43.65 Million SEK | -44.37% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -121.078% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 70.961% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 91.709% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -108.878% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 19.909% |
| Fluicell AB (publ) | 9.34 Million SEK | -574.785% |
| Genovis AB (publ.) | 288.85 Million SEK | 78.181% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 26.05% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 93.809% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 82.061% |
| Mendus AB (publ) | 755.95 Million SEK | 91.663% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 64.417% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 55.173% |
| I-Tech AB | 152.44 Million SEK | 58.657% |
| Intervacc AB (publ) | 259.61 Million SEK | 75.723% |
| Kancera AB (publ) | 65.64 Million SEK | 3.988% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 94.992% |
| LIDDS AB (publ) | 17.65 Million SEK | -256.981% |
| Lipum AB (publ) | 12.11 Million SEK | -420.437% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -87.563% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 77.39% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -214.48% |
| Nanologica AB (publ) | 77.42 Million SEK | 18.603% |
| NextCell Pharma AB | 81.28 Million SEK | 22.467% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 73.561% |
| OncoZenge AB (publ) | 20.34 Million SEK | -209.857% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -645.416% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -50.206% |
| Saniona AB (publ) | 64.14 Million SEK | 1.743% |
| Simris Alg AB (publ) | 174.55 Million SEK | 63.893% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -18.949% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -1.039% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -190.399% |
| SynAct Pharma AB | 228.01 Million SEK | 72.36% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 87.3% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 90.356% |
| Xintela AB (publ) | 18.39 Million SEK | -242.62% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 91.764% |
| Ziccum AB (publ) | 14.97 Million SEK | -320.952% |